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Abstract
Background/Aims: AQP2 expression is mainly controlled by vasopressin-dependent changes 
in protein abundance which is in turn regulated by AQP2 ubiquitylation and degradation, 
however the proteins involved in these processes are largely unknown. Here, we investigated 
the potential role of the CHIP E3 ligase in AQP2 regulation. Methods: MCD4 cells and kidney 
slices were used to study the involvement of the E3 ligase CHIP on AQP2 protein abundance 
by cell homogenization and immunoprecipitation followed by immunoblotting. Results: 
We found that AQP2 complexes with CHIP in renal tissue. Expression of CHIP increased 
proteasomal degradation of AQP2 and HSP70 abundance, a molecular signature of HSP90 
inhibition. Increased HSP70 level, secondary to CHIP expression, promoted ERK signaling 
resulting in increased AQP2 phosphorylation at S261. Phosphorylation of AQP2 at S256 
and T269 were instead downregulated. Next, we investigated HSP70 interaction with AQP2, 
which is important for endocytosis. Compared with AQP2-wt, HSP70 binding decreased in 
AQP2-S256D and AQP2-S256D-S261D, while increased in AQP2-S256D-S261A. Surprisingly, 
expression of CHIP-delUbox, displaying a loss of E3 ligase activity, still induced AQP2 
degradation, indicating that CHIP does not ubiquitylate and degrade AQP2 itself. Conversely, 
the AQP2 half-life was increased upon the expression of CHIP-delTPR a domain which binds 
Hsc70/HSP70 and HSP90. HSP70 has been reported to bind other E3 ligases such as MDM2. 
Notably, we found that co-expression of CHIP and MDM2 increased AQP2 degradation, 
whereas co-expression of CHIP with MDM2-delRING, an inactive form of MDM2, impaired 
AQP2 degradation. Conclusion: Our findings indicate CHIP as a master regulator of AQP2 
degradation via HSP70 that has dual functions: (1) as chaperone for AQP2 and (2) as an 
anchoring protein for MDM2 E3 ligase, which is likely to be involved in AQP2 degradation
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IntroductionBody water homeostasis is directly regulated by the hormone vasopressin (AVP) which 
controls the expression and the trafficking of the water channel AQP2. During dehydration 
and hypernatremia, AVP is secreted by the pituitary gland and binds type-2 receptor 
(V2R) at the basolateral membrane of renal collecting duct principal cells [1-4]. Activation 
of the cAMP/PKA signal transduction pathway stimulates the translocation of AQP2-
bearing vesicles to the apical plasma membrane increasing luminal permeability [5-7]. 
This translocation is paralleled by AVP-dependent phosphorylation of AQP2 at serine-256 
(pS256). Nevertheless, several studies have revealed that phosphorylation at S256 is not 
necessary for exocytosis as well as dephosphorylation is not required for endocytosis. 
Instead, it has been hypothesized that pS256 may play a role in controlling the kinetics of 
endocytosis [8]. Blocking clathrin-dependent endocytosis, by expressing GTPase-deficient 
dynamin mutation (K44A) or with methyl-β-cyclodextrin, enhances the abundance at 
the plasma membrane of both wild-type AQP2 and AQP2 that cannot be phosphorylated 
at serine 256 (S256A) [9], indicating that the constitutive trafficking is not regulated by 
phosphorylation at S256. In the last few years, the understanding of regulation of AQP2 
trafficking was improved by extensive investigations of Knepper’s group demonstrating 
that AQP2 can also be phosphorylated at serine-261 (S261), serine-264 (S264) and 
serine/threonine-269 (S/T269) [10]. Time course of vasopressin-dependent AQP2 
phosphorylation indicated that S256 phosphorylation is necessary as a priming event for 
phosphorylation at S264 and S/T269 or dephosphorylation at S261 [11]. Phosphorylation 
at S/T269 compartmentalized AQP2 exclusively in the apical plasma membrane therefore 
it can be considered a membrane retaining signature [11].The expression level of integral membrane proteins in the plasma membrane 
results from a balance between exocytosis and endocytosis. Several studies revealed that 
accumulation of AQP2 at the apical plasma membrane can also occur in the absence of 
stimulation with vasopressin by inhibiting constitutive endocytosis [9] or by inducing 
actin depolymerization [12, 13]. However, the molecular machinery controlling docking 
and fusion of AQP2-bearing vesicles, as well as the endocytosis and degradation of AQP2 
remains to be further clarified. The trafficking of AQP2 bearing vesicles involves actin 
remodeling, SNARE, Rab proteins and myosin as few examples of the complex group of 
proteins involved in regulating the trafficking of AQP2 [12-15]. It remains to be clarified 
whether these proteins play a role in controlling the constitutive trafficking or the 
vasopressin dependent AQP2 redistribution. Up to now, few studies have demonstrated 
the direct interaction between AQP2 and the components of trafficking machinery. Among 
them, the functional involvement of annexin-2 in the fusion process of AQP2 vesicles has 
been demonstrated [15]. Specifically, annexin-2 binds directly AQP2 [16] and associates to 
the lipid raft under forskolin-induced cAMP production [15]. Statins, cholesterol synthesis 
inhibitors, lowered raft cholesterol content and accumulated AQP2 at the plasma membrane 
by inhibiting the endocytosis via Rho proteins, independently of cAMP/PKA signaling [17, 
18]. The endocytotic pathway is quite complex and involves selective protein-protein 
interactions. The heat shock 70 (HSP70) family members include multiple homologs such 
as the cytosolic stress-induced HSP70 (HSP72), Hsc70 and the ER-localized BiP [19, 20].
Importantly, HSP70 associates directly to AQP2 and controls the internalization 
process [21]. Functional knockdown of HSP70/hsc70 increased the abundance of AQP2 
at the plasma membrane due to inhibition of endocytosis [21], which targets AQP2 in a 
recycling vesicles pool or to the degradation route. Short-chain ubiquitylation at lysine 
270 (K270), enhances AQP2 endocytosis and lysosomal degradation [22]. Instead, AQP2 
polyubiquitylation targets AQP2 for proteasomal degradation [23]. Bioinformatical 
studies proposed NEDD4 and NEDD4L, AMFR, STUB1, ITCH, ZFPL1 as possible E3 ligases 
responsible for AQP2 ubiquitylation [24]. Furthermore, transcriptome analysis and biochemical studies revealed that vasopressin stimulation changed the protein abundance 
of three E3 ligases named BRE1B, NEDD4, and CUL5 [25]. The present study aims to clarify 
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intracellular signals controlling AQP2 stability. Specifically, we found that the expression of 
the E3 ligase CHIP increases AQP2 degradation via HSP70, which interacts with AQP2 and 
anchors the E3 ligase MDM2, apparently involved in modulating AQP2 degradation. A novel 
pathway controlling AQP2 stability was therefore unraveled and we propose the E3-ligase 
CHIP and MDM2 novel players in modulating the abundance of AQP2.
Materials and Methods
Chemicals and reagents
All chemicals were purchased from Sigma-Aldrich (Milan, Italy). MG132 (Carbobenzoxy-L-leucyl-
L-leucyl-L-leucinal) was obtained from AdipoGen AG (Liestal, Switzerland). 17AAG (17-(Allylamino)-
17-demethoxygeldanamycin) was purchased from Santa Cruz Biotechnology (DBA, Milan Italy). PEI 
(Polyethylenimine, Linear, MW 25, 000) was purchased from Polysciences Inc. (Germany). Lipofectamine 
was purchased from Life Technologies (Monza, Italy).
Antibodies
To detect the total amount of AQP2, antibodies against the 20 amino acid residue segment just 
N-terminal from the poly-phosphorylated region of rat AQP2 (CLKGLEPDTDWEEREVRRRQ) were used 
[26]. AQP2-pS256 and AQP2-pT269 antibodies were described by Trimpert et al [27].. AQP2-pS261 
antibodies were purchased from Novus Biological (DBA, Milan Italy). Monoclonal antibody against CHIP, 
monoclonal antibody against c-Myc (9E10) and anti-MDM2 (C-18) were purchased from Santa Cruz 
Biotechnology (DBA, Milan Italy). Polyclonal antibody Anti-phospho-MAPKinase 1/2 (Erk 1/2) (Thr185/
Tyr187, clone AW39) and monoclonal antibody Anti-Erk1/2 (p44/42, clone MK12) were bought from 
Millipore (Milan, Italy). Monoclonal antibody against HSP70 (C92F3A-5) was from Enzo Life Sciences (3V 
Chimica S.r.l., Roma, Italy). This antibody is specific for HSP70 family members (i.e. HSP72) but do not 
cross-react with Hsc70. Secondary goat anti-rabbit and goat anti-mouse antibodies were purchased from 
Sigma-Aldrich (Milan, Italy).
DNA constructs
Myc-CHIP, Myc-Δ tetratricopeptide repeat (TPR) CHIP and Myc-ΔUboxCHIP were already described 
[28].
pcDNA3-MDM2 and pcDNA3-MDM2-del1-441 were obtained by Dr. Tullo [29]. The empty vector 
pCDNA 3.1, pCB6-hAQP2, pCB6-hAQP2-S256A, pCB6-hAQP2-S256D, pCB6-hAQP2-S261A, pCB6-hAQP2-
S261D and pCB6-hAQP2-S256DS261D, pCB6-hAQP2-S256DS261A have been described [30, 31].
Cell culture and transfection
Mouse cortical collecting duct M-1 and MCD4 cells [32], were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM/F12) supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 100i.u./ml penicillin, 
100 µg/ml streptomycin and 5 µM dexamethasone at 37°C, 5% CO2.
Cells were transiently transfected with plasmids (0.4 µg of DNA/cm2) encoding for CHIP-wt and its 
variants, using lipofectamine (1 mg/ml) according to the protocol provided by the manufacturer (Life 
Technologies, Monza, Italy). Experiments were performed 48 h post-transfection. Alternatively, cells were 
seeded a day prior to transfection at 80% confluence in 100 mm diameter Petri dishes. PEI 1 μg/μl was 
dissolved with 150  mM NaCl (pH 7) and incubated for 5 min at room temperature. In parallel, 6 μg of 
DNA were diluted in NaCl 150 mM. After 5 min, solutions were mixed, vortexed and incubated for 20 min 
at room temperature. Transfecting solution was then added to cells and incubated for 8 h in complete 
medium at 37°C, 5% CO2. Immunoprecipitation experiments were performed 48 h after transfection.
Treatment and cells preparation
MCD4 cells were seeded in 12-well plates and assayed 48 h post transfection. Cells were left in the 
basal condition or stimulated with Chloroquine (0.1 mM) over night, with MG132 (10 μM) for 4 hours or 
with 2 μM 17-AAG for 2, 3 or 4 h, followed by the addition of 100 μg/ml Cycloheximide for 1, 2 or 4 hours. 
Alternatively, cells were treated with FR180204 5 µM for 30 min. Then, cells were scraped and sonicated. 
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The obtained lysates were resuspended in Laemmli’s buffer 6X (350 mM Tris-HCl pH 6.8, 10% SDS, 50% 
Glycerol and 0.03% Bromophenol blue) in the presence of proteases (1 mM PMSF, 2 mg/ml leupeptin 
and 2 mg/ml pepstatin A) and phosphatases (10 mM NaF and 1 mM sodium orthovanadate) inhibitors. 
The obtained homogenates were sonicated at 80 Hz amplitude for 10 sec and used for immunoblotting 
studies. Alternatively, cells were cultured in 100 mm diameter Petri dishes and grown to confluence for 3 
days. Then, cells were washed twice in ice-cold PBS and scraped in ice-cold Isolation Medium (220  mM 
mannitol, 70 mM sucrose, 0, 5 M EGTA pH 8, 0, 5 M EDTA pH 8, 1 M Tris-HCl, pH 7.4) in the presence of 
proteases (1 mM PMSF, 2 mg/ml leupeptin and 2 mg/ml pepstatin A) and phosphatases (10 mM NaF and 
1 mM sodium orthovanadate) inhibitors. Cell suspension was homogenized manually with a mini-potter 
and spun at 8, 000xg for 20 min. The supernatant was centrifuged at 17, 000xg for 1 hour to obtain a pellet 
enriched in plasma membranes and the resulting supernatant was subjected to a last centrifugation step 
for 1 hour at 200, 000xg in a Beckman Rotor TLA 120.1. The final pellet, enriched in intracellular vesicles, 
was gently resuspended in Isolation medium using a 30-gauge needle. Equal amount of proteins (30 µg/
lane) were subjected to electrophoresis and immunoblotting.
Immunoprecipitation
Immunoprecipitation experiments were performed as described [33]. Briefly, mice kidney medulla, 
fresh kidney slices, MCD4 or M1 cells were lysed with 1% Triton X-100, 150 mM NaCl, 25 mM HEPES (pH 
7.4) in the presence of protease (1 mM PMSF, 2 mg/ml leupeptin and 2 mg/ml pepstatin A) and phosphatase 
(10 mM NaF and 1 mM sodium orthovanadate) inhibitors. Lysates were clarified by centrifugation at 
13, 000 g for 15 minutes at 4°C. The obtained supernatants were precleared with protein A-sepharose 
suspension for 30 min under rotation at 4°C. Pre-cleared lysates were incubated overnight with anti-AQP2 
or anti-HSP70 antibodies coupled to protein A-Sepharose. Immunocomplexes were washed three times, 
resuspended in Laemmli’s buffer in not denaturating conditions and subjected to immunoblotting using 
anti-AQP2, anti-HSP70, anti-c-Myc and anti-MDM2 antibodies.
Kidney slices
Studies in kidney slices were performed as reported [6]. Briefly, kidney were quickly removed, and 
thin transversal slices (500 μm), including the cortex and the medulla, were cut using a McIlwain Tissue 
Chopper (Ted Pella Inc.; Redding, CA, United States). The slices were equilibrated for 10 min in Kidney 
Slices buffer containing 118 mM NaCl, 16 mM HEPES, 17 mM Na-HEPES, 14 mM Glucose, 3.2 mM KCl, 
2.5 mM CaCl2, 1.8 mM MgSO
4
, 1.8 mM KH
2
PO
4
. Subsequently, kidney slices were left in the same buffer at 
37°C or incubated with 17AAG (10 µM) for 30 min. The treated sections were then homogenized with a 
mini-potter in ice-cold kidney slices buffer, in the presence of proteases (1 mM PMSF, 2 mg/ml leupeptin 
and 2 mg/ml pepstatin A) and phosphatases (10 mM NaF and 1 mM sodium orthovanadate) inhibitors. 
Suspensions were then centrifuged at 12, 000xg for 10 min at 4°C and the supernatants used for western 
blotting analysis.
Gel Electrophoresis and Western blotting
Proteins were separated on 13% bis-tris acrylamide gels under reducing conditions. Protein bands 
were electrophoretically transferred onto Immobilon-P membranes (Millipore Corporate Headquarters, 
Billerica, USA) for Western blot analysis, blocked in TBS-Tween-20 containing 3% BSA and incubated 
with primary antibodies overnight. Immunoreactive bands were detected with secondary antibodies 
conjugated to horseradish peroxidase (HRP) obtained from Santa Cruz Biotechnologies (Tebu Bio, Milan, 
Italy). Membranes were developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, USA) with Chemidoc System (Bio-Rad Laboratories, Milan, Italy). Representative ﬁgures are 
shown. Densitometry analysis was performed with Scion Image. Data were summarized in histograms 
with GraphPad Prism (Graphpad Software Inc. La Jolla, CA, USA)
Statistical Analysis
Data are reported as means ± SEMs. Statistical analysis was performed by one-way ANOVA and two-
way ANOVA, followed by Tukey’s multiple comparison test. When applicable, Student t-test student was 
also applied. A difference of P<0.05 was considered statistically significant.
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Results
AQP2 associates with CHIP in renal tissue
Protein sequencing analysis revealed that AQP2 contains within its C-terminal domain 
the SXS motif which can bind the E3 ligase CHIP directly [34]. Co-immunoprecipitation 
experiments were performed to evaluate the putative interaction between AQP2 and the 
E3-ligase CHIP. To this end, MCD4 cells and mouse kidney lysates were incubated with anti-
AQP2 antibodies, next, the immunocomplexes were precipitated with protein-A Sepharose 
and analyzed by immunoblotting with antibodies specific for CHIP. AQP2 antibodies were 
used as control of the immunoprecipitation experiments. The obtained results indicate that 
AQP2 can complex with CHIP in MCD4 cells (Fig. 1A) and in renal tissue (Fig. 1B).
Expression of CHIP reduces AQP2 abundance
To investigate the possible involvement of CHIP in AQP2 expression levels, the mouse 
collecting duct cells M1, stably transfected with human AQP2, were used as experimental 
model (MCD4 cell line) [32]. Cellular fractionation experiments revealed that CHIP co-
fractionated mainly in the cytosol with a weak expression in the 17, 000xg and in the 200, 
000xg pellets (Fig. 2). To assess the functional role of CHIP on the cellular abundance of 
AQP2, MCD4 cells were transfected with Myc-CHIP. All experiments were performed 48 
hours after transfection. The protein synthesis inhibitor cycloheximide (CHX, 100 μg/ml) 
was added to MCD4 to abolish de novo protein synthesis. The abundance of AQP2 at 1, 2 
and 4 hours after CHX treatment was analyzed by immunoblotting (Fig. 3). Compared with 
MCD4 cells not expressing CHIP (mock, Fig. 3A), AQP2 abundance significantly decreased 
within one hour of CHX incubation in cells expressing CHIP-wt (Fig. 3B). Several studies 
showed that AQP2 can be targeted for degradation either to the lysosome pathway or to 
the proteasomal route [22, 23]. To evaluate whether the expression of CHIP marks AQP2 
for degradation in the lysosomes, cells expressing CHIP were incubated overnight with 
chloroquine (0.1 mM), a known lysosome inhibitor (Fig. 4A). Chloroquine treatment did 
not impair the CHIP-induced decrease of AQP2 abundance. In contrast, a 4 hours incubation 
with the proteasome inhibitor MG132 (10 μM),  abolished the CHIP-dependent decrease of 
AQP2 expression within one hour of CHX treatment (Fig. 4B).
Expression of CHIP increases HSP70 abundance
Protein homeostasis depends on controlled folding and protein degradation. Several 
co-chaperones play fundamental roles in regulating the transit of the client protein. 
Nevertheless, co-chaperones are also involved in ubiquitin-mediated proteasomal 
degradation. The C-terminal HSP70 binding protein (CHIP) associates with HSP70 
and HSP90 through its tetratricopeptide domain (TRP) and acts as E3 ligase via the 
U-box domain which is a modified RING finger motif [35]. Moreover, CHIP increases the 
expression of  HSP70 by stimulating HSF1 which is required for protection against stress-
induced apoptosis [36]. Compared to mock cells, expression of CHIP significantly increases 
the abundance of HSP70 (Fig. 5). To exclude that the increased expression of HSP70 was 
Fig. 1. AQP2 and CHIP co-immunoprecip-
itation in renal tissue. AQP2 was immuno-
precipitated (I.P. AQP2) using pre-C-tail an-
tibodies from MCD4 cells (A) and from fresh 
mouse kidney slices (B). Whole cell lysates 
were also subjected to precipitation with only protein A-coupled Sepharose (ProtA) 
or with nonspecific IgG. Immunocomplexes were analyzed by immunoblotting with an-
tibodies specific for CHIP; anti-AQP2 antibodies were used as control of the immunoprecipitation experi-
ments. The obtained results indicate that AQP2 can complex with CHIP in MCD4 cells and in renal tissue.
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due to the transfection itself, MCD4 cells were further transfected with an empty vector 
(pcDNA3.1) containing CMV promoter but without CHIP cDNA. As shown in figure 5, the 
transfection with the empty plasmid did not alter the cellular abundance of HSP70, thereby 
indicating that CHIP itself leads to an increased abundance of HSP70.
HSP90 inhibition reduces the cellular abundance of AQP2 in vitro and in ex vivo
Based on previous studies, the increased expression of HSP70 can be considered 
a “molecular signature” of HSP90 inhibition [37]. Consistent with that, 17AAG, a known 
inhibitor of HSP90, significantly increased the cellular abundance of HSP70 [38]. To better 
define the involvement of these heat shock proteins on AQP2 stability through signaling 
activated by CHIP, MCD4 cells (mock) (Fig. 6A) and cells expressing CHIP (CHIP-wt) (Fig. 
6B) were left untreated or incubated with 17AAG (2 μM) for 2, 3 and 4 hours in the presence 
of CHX (100 μg/ml). Treatment with 17AAG significantly reduced the abundance of AQP2 
in cells not expressing CHIP (mock).  In CHIP expressing cells, the expression of AQP2 was 
reduced regardless of 17AAG treatment. Moreover, in CHIP expressing cells, no additive 
effect on AQP2 degradation was observed under treatment with 17AAG, suggesting that 
17AAG and expression of CHIP may converge on a similar intracellular pathway that involves 
the inhibition of HSP90. To assess the effect of 17AAG in renal tissue, ex vivo experiments 
were performed using fresh kidney slices (Fig. 7A). Renal slices were prepared and treated 
as described under experimental procedures. Immunoblotting analysis revealed that 
incubation with 17AAG significantly decreased the abundance of AQP2 compared with 
Fig. 2. Subcellular distribution of 
CHIP protein in MCD4 cells. MCD4 cells total homogenates, plasma membrane, intracellular vesicles and cytosol were isolated and ana-
lyzed by Western Blotting. Cellular fractionation experiments revealed 
that CHIP is mainly expressed in the homogenate and in the cytosol, 
although weak immunodetectable 
bands also appeared in the 17,000xg 
and in the 200,000xg pellets. Anti-
bodies against Actin and NaK were 
used to confirm the purity of the iso-
lated fractions.
Fig. 3. AQP2 abundance in MCD4 cells decreased after protein 
synthesis inhibitor cycloheximide (CHX) treatment. Cells stably 
expressing AQP2 were transiently transfected with CHIP-wt. Cells 
were treated with 100 µg/ml cycloheximide (CHX) for indicated 
time, and cell lysates were subjected to immunoblotting with anti-
AQP2 antibodies. Equal amounts of protein (30 μg/lane) were sep-
arated by gel electrophoresis and immunoblotted with anti-AQP2 
antibody. The loading control by Coomassie staining is also shown. 
Densitometric analysis revealed that cycloheximide (CHX) caused a 
significant decrease in AQP2 expression (52.82 ± 3.2%) within an 
hour of CHX incubation in cells expressing CHIP-wt (B) with respect 
to mock cells (A) (n= 3).
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untreated slices (Fig. 7B). Together these 
data suggest that HSP90 inhibition is crucial 
to balance the total content of AQP2 in cells 
and in renal tissue.
Expression of CHIP stimulates phosphorylation of ERK and changes the dynamic balance 
of the phosphorylation pattern of AQP2
Several studies showed that treatment with 17AAG upregulates HSP70 [38, 39] that participates in intracellular signaling pathways by binding different co-chaperones such as 
CHIP [40]. HSP70 functions as ATP-dependent molecular chaperone through activation of 
the ERK signaling [41]. To test the hypothesis that HSP70 promotes ERK phosphorylation, 
secondary to the expression of CHIP, immunoblotting experiments were performed (Fig. 
8A). To this end, MCD4 cells were left untransfected (mock) or transfected with CHIP-wt, as 
described in the experimental procedures. Immunoblotting studies revealed that exogenous 
expression of CHIP increases the phosphorylation of ERK compared to that observed in 
mock cells. Furthermore, incubation of CHIP expressing cells with FR180204, a selective ERK 
Fig. 4. CHIP dependent 
AQP2 degradation was me-
diated by proteasomes. (A) 
Effect of lysosome inhibitor 
Chloroquine on AQP2 deg-
radation. MCD4 cells tran-siently transfected with 
CHIP-wt were left under basal condition or incu-
bated with Chloroquine 0.1 
mM overnight. Cells were 
then treated with 100 µg/
ml cycloheximide (CHX). 
Total lysates (30 μg/lane) 
were subjected to immu-
noblotting for total AQP2. 
The loading control by Coo-massie staining is shown 
on the left of each panel. 
Densitometric analysis re-
vealed that Chloroquine treatment did not impair the CHIP-induced decrease of AQP2 abundance (n=3). (B) Effect 
of the proteasome inhibitor MG132 on AQP2 degradation. Cells transiently transfected with CHIP-wt were left 
under basal condition or stimulated with 10 µM MG132 for 4 h, simultaneously 100 µg/ml cycloheximide (CHX) 
was added for 1 or 2 h. Total lysates were subjected to immunoblotting for total AQP2. Densitometric analysis 
revealed that incubation with MG132 abolished the CHIP-dependent decrease of AQP2 expression within an hour 
of CHX treatment (n=3).
Fig. 5. Expression of CHIP increased HSP70 abun-
dance. (A) MCD4 cells were transiently transfected 
with CHIP-wt or its empty vector pC-DNA 3.1. After transfection, cells were lysed and equal amounts of 
protein (30 μg/lane) were separated by gel electro-
phoresis and immunoblotted with anti-HSP70 anti-
body. The loading control by Coomassie staining is 
shown. (B) Densitometric analysis (means ± SEMs) 
revealed a significant increase of HSP70 in CHIP-wt 
expressing cells (n= 3, *P<0.001) compared to mock.
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inhibitor, abolished the CHIP-dependent upregulation 
of ERK phosphorylation (Fig. 8A). Importantly, JNK 
and ERK can phosphorylate in vitro AQP2 at S261, a 
residue displaying a significant downregulation in its phosphorylation state under vasopressin stimulation 
in vivo [42]. Immunoblotting experiments (Fig. 8B) 
showed that the phosphorylation of AQP2 at S261 
increased in CHIP expressing cells (CHIP-wt) compared 
to that observed in mock cells. CHIP-dependent 
phosphorylation of AQP2 at S261 was abolished in the 
presence of the ERK inhibitor FR180204 suggesting that ERK is the kinase committed to 
phosphorylate AQP2 at S261, secondary to CHIP expression.
Phosphorylation events are fundamental to control the cellular fate of AQP2 and thus 
urinary concentration. Inhibition of p38-MAPK reduced the phosphorylation of AQP2 at 
S261 preventing proteasomal degradation thereby enhancing AQP2 stability [23]. As stated 
above,  phosphorylation at S256 is important but not essential for the insertion of AQP2 
at the apical plasma membrane [43] and AQP2 is retained in the apical membrane when 
phosphorylated at S/T269. To evaluate whether the expression of CHIP (CHIP-wt) alters 
the phosphorylation balance of AQP2, immunoblotting studies were performed (Fig. 9A). 
Immunoblotting analysis revealed that the expression of CHIP significantly decreased the 
phosphorylation at S256 and T269, while increased the pS261 compared to the signals 
detected in cells not transfected with CHIP-wt (mock) (Fig. 9B).
Fig. 6. 17AAG-induced 
HSP90 inhibition pro-
moted AQP2 degradation. 
MCD4 cells (mock (A) or 
expressing CHIP-wt (B)) were left untreated or incu-
bated with 17AAG 2 µM for 
2, 3 or 4 hours in the pres-
ence of CHX 100 µg/ml. 
Cells were lysed and equal 
amounts of protein (30 μg/lane) were separated by gel electrophoresis and immu-
noblotted with anti-AQP2 
antibody. The loading con-
trol by Coomassie staining 
is shown. Statistical analysis of data (means ± SEMs) revealed that treatment with 17AAG significantly 
reduced AQP2 abundance in mock cells similarly to that observed in CHIP-wt expressing cells. In CHIP 
expressing cells, AQP2 expression was reduced regardless of 17AAG treatment.
Fig. 7. Effect of 17AAG on AQP2 expression in mouse kidney 
slices. (A) Renal slices were treated with or without 17AAG (10 
μM) for 30 min. Kidney slices were lysed and equal amounts of 
protein (30 μg/lane) were separated by gel electrophoresis and 
immunoblotted with anti-AQP2 antibody. The loading control by 
Coomassie staining is shown. (B) Signals were semiquantified 
by densitometry. Statistical analysis of data (means ± SEMs) re-
vealed that incubation with 17AAG significantly decreased AQP2 
abundance with respect to untreated slices (Untreated=1±0.1, 
17AAG=0.7±0.09, n= 3, *P<0.01).
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CHIP can switch HSP70/HSP90 complexes from protein folding to protein degradation 
via proteasomes [35]. Interestingly, HSP70 binds AQP2 directly and an intact S256 
residue is crucial for this interaction [21]. Here, to investigate whether changes in AQP2 
phosphorylation at S256 and S261 modulates the interaction with HSP70, several AQP2 
mutants [30, 31] were transfected in M1 cells. Co-immunoprecipitation experiments showed 
that point mutations at S261 either with D, mimicking the constitutive phosphorylated 
form, or with A, mimicking the constitutive not phosphorylated protein, do not alter the 
interaction ability of AQP2 with HSP70 (Fig. 10A, lane 2-3). Conversely, similarly to what 
found by Lu et at [21]., single mutation at S256 with D reduced the binding ability of AQP2 
and HSP70. Moreover, double mutations at S256 and S261 with D (AQP2-S256D-S261D) also reduced this protein association similarly to what was observed in cells expressing the 
AQP2-S256D mutant. In contrast, double mutations at S256 with D and S261 with A (AQP2-
S256D-S261A) increased the HSP70/AQP2 interaction. Densitometric analysis (Fig. 10B) 
reveals a significant upregulation of the HSP70/AQP2-S256D-S261A binding compared to 
HSP70/AQP2-wt ratio, fixed as 1 (Fig. 10 lane 5, AQP2-S256D-S261A: 1, 59 ±0.10 vs AQP2 
wt: 1; p<0, 05).
Fig. 8. Expression of CHIP stimulated 
ERK phosphorylation and increased AQP2 
phosphorylation at S261. (A) MCD4 cells 
were transfected with CHIP-wt and left under basal condition or stimulated with 
FR180204, a selective ERK inhibitor. Sta-
tistical analysis of data (means ± SEMs) 
revealed that CHIP significantly increased 
ERK phosphorylation compared to that 
observed in mock cells (n=5, *P<0.0001). 
Incubation of CHIP expressing cells with 
FR180204 abolished the CHIP-dependent 
upregulation of ERK phosphorylation. (B) 
MCD4 cells expressing CHIP-wt were left under basal condition or stimulated with 
FR180204. Endogenous expression of 
CHIP-wt was associated with a significant 
increase in AQP2 phosphorylation at S261 
(AQP2-pS261) in cells expressing CHIP-wt 
respect to untransfected cells (n=5, *P<0.01). Treatment of CHIP expressing cells with FR180204 abolished the 
CHIP-dependent increase of AQP2-pS261 (n=5, #P<0.0001).
Fig. 9. AQP2 phosphorylation balance was 
altered by CHIP expression. (A) MCD4 cells 
were left untransfected (mock) or transfect-
ed with CHIP-wt. After transfection, cells 
were lysates and subjected to immunoblot 
using antibodies against AQP2 phosphory-
lated at S256 (AQP2-pS256), S261 (AQP2-
pS261) or T269 (AQP2-pT269). (B) Densi-
tometric analysis (means ± SEMs) revealed 
a significant increase of AQP2-pS261 in 
CHIP expressing cells (n= 3, *P<0.005) and 
a significant decrease of AQP2-pS256 (n=3, 
*P<0.01) and AQP2-T269 (n=3, *P<0,05) 
compared to mock cells.
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The ubiquitin-protein ligase activity of CHIP is not 
required for AQP2 degradation: involvement of 
the E3 ligase MDM2
To assess whether CHIP participates directly in 
the degradation of AQP2, MCD4 cells were transiently 
transfected either with constructs coding for wild-type CHIP (CHIP-wt), or with CHIP-
delUbox, lacking the catalytic domain, or with CHIP-delTPR, which is deficient in the TPR 
domain needed for the interaction with chaperone proteins as HSP70. All proteins were 
expressed (Fig. 11A). AQP2 expression at 1 and 2 hours after CHX incubation was evaluated 
by Western Blotting (Fig. 11B). The loading control by Coomassie staining is also shown 
(Fig. 11C). Surprisingly, in cells expressing CHIP-delUbox, AQP2 degradation was similar 
to that measured in cells transfected with CHIP-wt (Fig. 11D) indicating that the ubiquitin 
ligase activity of CHIP is not required for AQP2 degradation. In contrast, expression of CHIP-
delTPR resulted in a relevant attenuation of AQP2 degradation underlining the crucial role 
of CHIP association with HSP70 to determine the fate of AQP2. Based on these findings, it 
was hypothesized that HSP70, anchored to the C-terminal domain of CHIP, tethers other 
E3-ligases. The E3 ligases Ubr, Cul5, Parkin, TRIM32 and MDM2 can complex with HSP90/
HSP70, targeting client proteins for degradation [44-46]. MDM2 plays an important role in 
renal physiology and pathophysiology [47-49]. To test the hypothesis that CHIP can complex 
with HSP70 and MDM2, co-immunoprecipitation experiments were performed (Fig. 12). 
Specifically, MCD4 cells were co-transfected with CHIP-wt and MDM2 and cell lysates were 
incubated with antibodies specific for HSP70. Immunocomplexes were precipitated with 
protein-A Sepharose and analyzed by immunoblotting with antibodies specific for α-myc, 
to detect CHIP, and MDM2; HSP70 antibodies were used as control (Fig. 12A). Alternatively, 
co-immunoprecipitation assays were carried out in cells co-expressing CHIP-delTPR and 
MDM2 (Fig. 12B). We observed that only CHIP-wt can complex with HSP70 recruiting MDM2 
in the same interactome (Fig. 12A). In contrast, CHIP-delTPR loses the ability to interact 
with HSP70 that still tethers MDM2 (Fig. 12B). To clarify the involvement of MDM2 in 
AQP2 degradation, MCD4 cells were transfected either with CHIP-wt or co-transfected with 
CHIP-wt and MDM2-wt. Alternatively, cells were co-transfected with CHIP-wt and MDM2-
delRING lacking the catalytic domain. AQP2 abundance was evaluated at 1 and 2 hours after 
CHX treatment (Fig. 13A). Immunoblot analysis (Fig. 13B) revealed that in cells expressing 
CHIP-wt, AQP2 degradation occurred similarly to that measured in cells co-transfected with 
CHIP-wt and MDM2-wt. In contrast, in cells expressing MDM2-delRING the reduction in 
AQP2 expression, observed within 1 hour of CHX incubation, was significantly attenuated. 
Together these findings suggest that MDM2 is the E3 ligase committed to promote AQP2 
degradation in CHIP expressing cells.
Fig. 10. HSP70 binding affinity was higher for AQP2-S256D-
S261A. (A) M1 cells were transfected with pCB6-hAQP2, 
pCB6-hAQP2-S256A, pCB6-hAQP2-S256D, pCB6-hAQP2-
S261A, pCB6-hAQP2-S261D, pCB6- hAQP2-S256DS261D, and 
pCB6-hAQP2-S256DS261A. 48 h after transfection, co-immu-
noprecipitation experiments were performed. (B) Statistical 
analysis of data (means ± SEMs) revealed that point mutations 
at AQP2-S261 either with D or with A did not alter the inter-
action ability of AQP2 with HSP70. Double mutations at S256 
and S261 with D, reduced this protein association similarly to 
what observed in cells expressing the AQP2-S256D mutant 
(n=3, *P< 0.01). In contrast, double mutations at S256 with D 
and S261 with A (AQP2-S256D-S261A) increased the HSP70/
AQP2 interaction (n=3, *P<0.01).
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Discussion
AQP2 expression is mainly controlled by vasopressin-dependent changes in protein 
abundance which is in turn regulated by AQP2 ubiquitylation and degradation. However the 
proteins involved in these processes are largely unknown. Here, we provide new findings 
regarding the potential role of the E3 ligases CHIP and MDM2 in AQP2 regulation.
Interestingly, AQP2 contains, within its C-terminal, the motif SXS, which is needed for 
direct interaction with the E3 ligase CHIP [34]. Consistent with this observation, AQP2 inter-
acts with the E3-ligase CHIP in renal tissue (Fig. 1). However, point mutation at S231 with A, 
within the SXS motif, in AQP2 did not alter the association between CHIP and AQP2 in renal 
collecting duct MCD4 cells (data not shown) likely indicating that accessory proteins may 
modulate this binding.
CHIP is only one player of multichaperone complexes consisting of several other chap-
erones. In the kidney, the thiazide-sensitive cotransporter, NCC, co-immunoprecipitates 
with multiple chaperones and co-chaperones such as HSP70, HSP90, HSP40, CHIP and HOP. 
These bindings are crucial for cellular fate of NCC [38]. CHIP overexpression controls sta-bility and promotes the degradation of several target proteins as the apoptosis suppressor 
(DDIAS), the potassium channel Kv1.5, the receptor tyrosine kinase AXL and several others 
[50-52]. We found here that overexpression of CHIP in MCD4 cells significantly decreased 
AQP2 abundance within one hour after CHX incubation. It cannot be excluded, however, that 
Fig. 12. CHIP complexes with HSP70 and MDM2 to promote 
AQP2 degradation. MCD4 cells were co-transfected with 
CHIP-wt and MDM2 (A) or CHIP-delTPR and MDM2 (B). 
48 h after transfection, cells were lysed and incubated with 
antibodies specific for HSP70. Immunocomplexes were precipitated with protein-A Sepharose and analyzed by 
immunoblotting with antibodies anti-myc or anti-MDM2; 
anti-HSP70 antibodies were used as control. Only CHIP-wt 
can complex with HSP70 recruiting MDM2 in the same in-
teractome (n = 6). In contrast, CHIP-delTPR lost the ability 
to interact with HSP70 that still tethers MDM2 (n = 6).
Fig. 11. CHIP dependent AQP2 degrada-
tion in cells expressing CHIP-delTPR, the 
CHIP mutant unable to bind HSP70/HSP90 
(A) CHIP mutants expression in MCD4. 
MCD4 cells were transfected with CHIP-wt, 
CHIP-delTPR, deficient in the TPR (tetratri-
copeptide) repeat, or CHIP-delUbox, lack-
ing the catalytic domain. Cell lysates were 
subjected to immunoblot using antibodies 
against c-Myc. (B) MCD4 cells were trans-
fected with CHIP-wt and its mutants and left under basal condition or incubated 
with 100 µg/ml cycloheximide (CHX) for 
indicated time. Cells were lysed and equal 
amounts of protein (30 μg/lane) were separated by gel electrophoresis and im-
munoblotted with anti-AQP2 antibody. The 
loading control by Coomassie staining is 
shown. Immunoreactive signals were semiquantified by densitometry indicating that expression of CHIP-
delTPR resulted in a significant decrease of AQP2 degradation compared to cells expressing CHIP-wt and 
CHIP-delUbox.
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at long term compensatory mechanism may also 
play a role in controlling AQP2 abundance and 
stability. Equal amount of proteins were loaded 
under any conditions and Coomassie staining was 
used as loading control in the Western Blotting, as 
GAPDH abundance significantly changed in cells 
expressing CHIP-wt and mutants (not shown).
 GAPDH indeed is wrongly considered a 
good housekeeping marker used to normalize 
mRNA and proteins as GAPDH expression is also modulated and can change under different 
physiological cellular conditions [53]. Client proteins of CHIP can be targeted either to 
lysosomes or to proteasomes for degradation [50, 54]. While short-chain ubiquitylation 
increases AQP2 endocytosis and lysosomal degradation [22], polyubiquitylation targets 
AQP2 to proteasomes, in fact MG132 treatment increased the stability of AQP2 by impairing 
its proteasomal degradation [23]. In the present study, we found that overexpression of 
CHIP reduces the abundance of AQP2 through proteasomal pathway, as MG132 completely 
abolished the CHIP-dependent decrease of AQP2 expression (Fig. 4).
HSP70 and HSP90 are members of multiprotein complexes playing a role in modulating 
protein folding and stability [19]. CHIP, as co-chaperone, can switch HSP70/HSP90 complex 
from folding to protein degradation [35]. It has been reported that increased expression of 
CHIP activates the stress pathway by inducing the nuclear translocation of HSF-1, and the 
stimulation of HSE containing stress responsive promoters, like HSP70 [36]. In line with 
these findings, we have found that the expression of CHIP results in a significant increase 
in HSP70 abundance (Fig. 5). Chemical inhibition of HSP90, with 17AAG, also increased 
HSP70 expression [39, 55], that can sequester the clients released by the inactive HSP90 
and trigger their degradation. Inhibition of HSP90 with 17AAG reduces AQP2 expression 
level in MCD4 cell not transfected with CHIP (mock). Conversely, no relevant effect on AQP2 
abundance was observed in CHIP-wt cells indicating that overexpression of  CHIP includes 
a selective downregulation of HSP90, secondary to the upregulation of HSP70.
Exposure of cells to different stresses leads to upregulation of heat shock proteins 
and the activation of the ERK signal pathway [41, 56]. Interaction between CHIP and 
ERK5 has been shown and mediates cardio-protective effects [57]. The ERK cascade plays 
a central role in vasopressin secretion and signaling. During dehydration vasopressin 
release is paralleled by increased phospho-ERK in VP-ergic termini of the pituitary [58]. 
In the kidney, vasopressin stimulation causes ERK activation as ERK inhibition with U0126 
impaired the vasopressin-induced AQP2 expression [59]. In contrast, more recent data 
showed that vasopressin reduces the level of ERK phosphorylation which has been shown 
to phosphorylate AQP2 at S261 [42, 60]. The reason of this discrepancy is unclear even 
though the decrease in the phosphorylation, at sites recognized by the MAP kinase, might 
Fig. 13. MDM2-induced AQP2 degradation in cells expressing 
CHIP-wt. (A) MCD4 cells were transfected with CHIP-wt alone, 
CHIP-wt and MDM2-wt or CHIP-wt and MDM2-delRING. After 
transfection cells were treated with 100 µg/ml cycloheximide 
(CHX) for 1 or 2 h and cell lysates were subjected to immu-
noblot with anti-AQP2 antibodies. The loading control by 
Coomassie staining is shown. (B) Densitometric analysis and 
statistical studies revealed that in CHIP-wt expressing cells, 
AQP2 degradation occurred similarly to that measured in 
cells co-transfected with CHIP-wt  and MDM2-wt (n = 6). In 
contrast, in MDM2-delRING expressing cells, AQP2 reduction 
observed within 1 hour of CHX treatment was significantly at-
tenuated (n = 6).
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support the finding, demonstrating that vasopressin reduces ERK activity [42]. Here, the 
increase of ERK phosphorylation in cells expressing CHIP, is paralleled by an increase in the 
phosphorylation of AQP2 at S261, which was attenuated when cells were incubated with a 
specific inhibitor of ERK.
Phosphorylations of AQP2 at the C-terminal domain play multiple roles in regulating 
the fate of AQP2. Previous studies revealed that the increase in pS261 was paralleled by an 
increase of AQP2 ubiquitylation [30]. Phosphorylation at S256 stimulates the vasopressin-
dependent translocation of AQP2 vesicles to the plasma membrane where it is retained by 
increased phosphorylation at S/T269. In the present study, we show that overexpression 
of CHIP alters the dynamic of AQP2 phosphorylations under basal conditions. Besides 
an increase in pS261, immunoblotting analysis revealed a significant decrease of pS256 
and pT269 compared to cells not expressing CHIP (Fig. 9). In the absence of hormonal 
stimulation AQP2 can constitutively traffic. In fact, under basal condition, the signal-
induced proliferation-associated 1 like 1 (Sipa1L1) binds the intracellular PDZ domain of 
AQP2 stimulating its endocytosis. Stimulation with vasopressin abolished this interaction 
reducing AQP2 endocytosis, thereby increasing the accumulation of AQP2 at the plasma 
membrane [61]. AQP2 also binds the signal-induced proliferation-associated gene-1 (SPA-
1) and this association in turn plays a role in modulating the cellular distribution of AQP2, 
as in SPA-1 deficient mice AQP2 fails to translocate to the luminal side of the collecting 
ducts under fluid restrictions [62]. Therefore, phosphorylations and interaction with 
accessory proteins are crucial to control the trafficking of AQP2. Nevertheless, it has been 
shown that constitutive recycling of AQP2 is not associated with phosphorylation at any 
C-terminal residues [63]. It is not clear, however, whether phosphorylation may modulate 
AQP2 interaction with proteins involved in endocytosis. Mutations of  S256 with D or with 
A equally impair the interaction of Hsc70 and AQP2 [21]. In this respect, we evaluated the 
involvement of phosphorylation at S256 and S261 on AQP2 association with HSP70. In 
cells expressing CHIP, we found that point mutations at S256 with D (AQP2-S256D; AQP2-
S256D-S261D) decrease the interaction of HSP70 and AQP2. In contrast, the double mutant 
at S256 with D and S261 with A (AQP2-S256D-S261A) displays a higher ability to associate 
with HSP70. Phosphorylation at S256 is determinant for AQP2 accumulation at the plasma 
membrane as AQP2-S256D¸ AQP2-S256D-S261D, AQP2-S256D-S261A always located at the 
apical plasma membrane regardless of hormonal stimulation [30, 64].
Time course of vasopressin-dependent AQP2 phosphorylation showed that S256 is 
the first phosphorylation event occurring after vasopressin stimulation. S261 becomes de-phosphorylated with a t
1/2
 of 10, 6 minutes [11] suggesting that just after few minutes of 
vasopressin action, AQP2 can be poly-phosphorylated at S256, S261 and S/T269. The temporal 
succession of phosphorylation at the C-terminal of AQP2 indicates that dephosphorylation 
of S261 occurs after S/T269 phosphorylation [65]. Thus, dephosphorylation at S261 may 
promote the association of AQP2 with the endocytotic machinery and accessory proteins 
such as HSP70. In this study, MCD4 cells were not stimulated with vasopressin or forskolin, 
nevertheless overexpression of CHIP altered the dynamic of AQP2 phosphorylations that 
probably generates a specific phospho-isoform of AQP2, which is preferentially targeted 
Fig. 14. Schematic model. Expression of CHIP, inhibiting HSP90, 
increases proteasomal degradation of AQP2 and HSP70 abun-
dance. Increased HSP70 level, secondary to CHIP expression, 
promotes ERK signaling which in turn increases AQP2 phos-
phorylation at S261. Phosphorylation of AQP2 at S256 and T269 
are instead downregulated. Since expression of CHIP-delUbox, 
displaying a loss of E3 ligase activity, still induced AQP2 degrada-
tion, we hypothesized that CHIP does not cause AQP2 ubiquiti-nation and degradation itself, but represents a possible anchor-
ing protein for MDM2 E3 ligase, which binds HSP70 and appears 
to be committed to AQP2 degradation.
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to HSP70/CHIP degradative pathway. Unexpectedly, the present data reveal that CHIP is 
not directly committed to reduce AQP2 abundance since deletion of the catalytic domain, 
the UBox, did not change AQP2 expression compared to CHIP-wt expressing cells. It may 
be assumed that CHIP-delUBox can form dimers with endogenous CHIP resulting in the 
formation of a functional dimeric complex. However, transfection with CHIP-delTPR 
attenuates the CHIP-induced AQP2 downregulation, underlying the importance of TPR 
domain which tethers chaperones. It cannot be excluded, however, the existence of a CHIP 
dependent signaling at the endoplasmic reticulum where HSP70/HSP90 protein folding 
occurs. Importantly, it has been shown that CHIP can switch HSP70/HSP90 complexes from 
protein folding to protein degradation [35]. In this regard, HSP70/HSP90 can associate with 
other E3 ubiquitin ligase proteins such as MDM2. Consistently, co-immunoprecipitation 
analysis confirms that CHIP-delTPR does not complex with HSP70 and MDM2 which 
instead is involved in decreasing AQP2 abundance in CHIP-wt cells. MDM2 is the major 
negative regulator of p53. Several studies, however, demonstrated that MDM2 plays 
multiple roles in modulating transduction cascades as NF-kB and cAMP/PKA signaling 
[66, 67]. MDM2 can ubiquitylate beta-arrestin-sequestered PDE4D5 [23, 30, 44, 56], that 
is involved in controlling vasopressin-regulated water reabsorption. Rolipram, a selective 
inhibitor of PDE4D5 activated AQP2 shuttle and thus the osmotic water permeability [68]. 
A likely hypothesis is that MDM2 participates in controlling the cAMP degrading system. 
On the other hand, deletion of MDM2 in renal tubular cells associates with strong kidney 
injury and extensive tubular dilation [67]. Interestingly, renal tubular dysfunctions were 
also observed in AQP2-null mice and it was postulated that this complex phenotype might 
be associated with a defect in the interaction between AQP2 and integrins [69]. Whether 
MDM2 controls this interaction remains to be explored.
To conclude, we report here that expression of CHIP increased proteasomal degradation 
of AQP2 (Fig. 14). This event occurs through the inhibition of HSP90, the upregulation of 
ERK/HSP70, which binds the AQP2, when it is simultaneously phosphorylated at S256 and 
dephosphorylated at S261. Moreover, the present data indicate that HSP70 tethers the E3 
ligase MDM2 which is directly involved in the AQP2 degradation. These data might contribute to better understand the molecular mechanisms underlying the actions of molecules or hormones such as ATP and dopamine, counteracting vasopressin response and targeting 
AQP2 for degradation [30]. Indeed, these findings might be of clinical relevance to human 
diseases characterized by overexpression or abnormal stimulation of CHIP signaling [70] .
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